Inetetamab in the treatment of human epidermal growth factor receptor 2 positive metastatic breast cancer with gastrointestinal dysfunction:a case report
Breast cancer is a common tumor in women.At present,solid tumors of breast cancer can achieve good curative effect through corresponding treatment,but human epidermal growth factor receptor 2(HER2)positive breast cancer is more aggressive and malignant,which needs to attract the attention of patients and medical personnel.A case of breast cancer with hormone receptor-negative,HER2-positive and gastrointestinal dysfunction was retrospectively analyzed.The patient was initially diagnosed with locally advanced inflammatory breast cancer with axillary lymph node metastasis and was treated with neoadjuvant chemotherapy and surgery.When the disease progressed 3 years after surgery,Inetetamab combined with albumin-paclitaxel was given,followed by Inetetamab targeted therapy alone,and the disease continued to be alleviated.It is suggested that Inetetamab is a good choice of monoclonal drugs for HER2-positive advanced breast cancer.
InetetamabMetastatic Breast cancerGastrointestinal dysfunctionHuman epidermal growth factor receptor 2 positive
维普
万方数据
